Enanta Pharmaceuticals Files DEF 14A with Executive Compensation Details

Ticker: ENTA · Form: DEF 14A · Filed: Jan 26, 2024 · CIK: 1177648

Enanta Pharmaceuticals Inc DEF 14A Filing Summary
FieldDetail
CompanyEnanta Pharmaceuticals Inc (ENTA)
Form TypeDEF 14A
Filed DateJan 26, 2024
Risk Levellow
Pages16
Reading Time19 min
Key Dollar Amounts$37,500
Sentimentneutral

Complexity: moderate

Sentiment: neutral

Topics: DEF 14A, Executive Compensation, Equity Awards, Enanta Pharmaceuticals, SEC Filing

TL;DR

<b>Enanta Pharmaceuticals filed its DEF 14A, detailing executive compensation and equity award valuations for 2021-2023.</b>

AI Summary

ENANTA PHARMACEUTICALS INC (ENTA) filed a Proxy Statement (DEF 14A) with the SEC on January 26, 2024. Enanta Pharmaceuticals Inc. filed a DEF 14A form on January 26, 2024. The filing pertains to the fiscal year ending September 30, 2023. The company's principal executive offices are located at 500 Arsenal Street, Watertown, MA. The filing includes data related to equity awards granted and their fair values for PEO and Non-PEO members across multiple years (2021-2023). Specific metrics like 'YearEndFairValueOfEquityAwardsGranted' and 'ChangeInFairValue' are detailed for different executive categories.

Why It Matters

For investors and stakeholders tracking ENANTA PHARMACEUTICALS INC, this filing contains several important signals. This filing provides transparency into how executive compensation is structured, particularly concerning equity awards, which can influence investor perception of management alignment. Understanding the changes in fair value of equity awards can offer insights into the company's performance and future outlook as perceived by its leadership.

Risk Assessment

Risk Level: low — ENANTA PHARMACEUTICALS INC shows low risk based on this filing. The filing is a routine DEF 14A, primarily disclosing executive compensation and related equity award data, with no immediate financial or operational performance indicators presented.

Analyst Insight

Investors should review the executive compensation details to understand potential incentives and their alignment with company performance and shareholder value.

Key Numbers

  • 2024-01-26 — Filing Date (DEF 14A filing date)
  • 2024-03-06 — Period of Report (Conformed period of report)
  • 0930 — Fiscal Year End (Company fiscal year end)
  • 617 607 0800 — Business Phone (Company business phone number)

Key Players & Entities

  • ENANTA PHARMACEUTICALS INC (company) — FILER
  • 0000950170-24-007956 (filing_id) — ACCESSION NUMBER
  • 2024-01-26 (date) — FILED AS OF DATE
  • 2024-03-06 (date) — CONFORMED PERIOD OF REPORT
  • 0001177648 (cik) — CENTRAL INDEX KEY
  • 2834 (sic_code) — STANDARD INDUSTRIAL CLASSIFICATION
  • 500 ARSENAL STREET (address) — BUSINESS ADDRESS STREET 1
  • WATERTOWN (city) — BUSINESS ADDRESS CITY

Forward-Looking Statements

  • Enanta Pharmaceuticals will hold its annual shareholder meeting around the conformed period of report date. (ENANTA PHARMACEUTICALS INC) — high confidence, target: 2024-03-06

FAQ

When did ENANTA PHARMACEUTICALS INC file this DEF 14A?

ENANTA PHARMACEUTICALS INC filed this Proxy Statement (DEF 14A) with the SEC on January 26, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by ENANTA PHARMACEUTICALS INC (ENTA).

Where can I read the original DEF 14A filing from ENANTA PHARMACEUTICALS INC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ENANTA PHARMACEUTICALS INC.

What are the key takeaways from ENANTA PHARMACEUTICALS INC's DEF 14A?

ENANTA PHARMACEUTICALS INC filed this DEF 14A on January 26, 2024. Key takeaways: Enanta Pharmaceuticals Inc. filed a DEF 14A form on January 26, 2024.. The filing pertains to the fiscal year ending September 30, 2023.. The company's principal executive offices are located at 500 Arsenal Street, Watertown, MA..

Is ENANTA PHARMACEUTICALS INC a risky investment based on this filing?

Based on this DEF 14A, ENANTA PHARMACEUTICALS INC presents a relatively low-risk profile. The filing is a routine DEF 14A, primarily disclosing executive compensation and related equity award data, with no immediate financial or operational performance indicators presented.

What should investors do after reading ENANTA PHARMACEUTICALS INC's DEF 14A?

Investors should review the executive compensation details to understand potential incentives and their alignment with company performance and shareholder value. The overall sentiment from this filing is neutral.

How does ENANTA PHARMACEUTICALS INC compare to its industry peers?

Enanta Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development of small molecule drugs for treating liver diseases and other serious illnesses.

Are there regulatory concerns for ENANTA PHARMACEUTICALS INC?

The DEF 14A filing is a proxy statement required by the SEC for publicly traded companies, providing information on corporate governance, executive compensation, and matters to be voted on by shareholders.

Industry Context

Enanta Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development of small molecule drugs for treating liver diseases and other serious illnesses.

Regulatory Implications

The DEF 14A filing is a proxy statement required by the SEC for publicly traded companies, providing information on corporate governance, executive compensation, and matters to be voted on by shareholders.

What Investors Should Do

  1. Review the specific details of equity awards granted to PEO and Non-PEO members for 2021-2023.
  2. Analyze the 'ChangeInFairValue' metrics to understand potential executive perceptions of company performance.
  3. Compare executive compensation structures with industry peers if similar data is available.

Year-Over-Year Comparison

This filing is a DEF 14A, which typically follows a regular annual schedule. Specific comparative data from a previous filing is not directly extractable from the provided text.

Filing Stats: 4,735 words · 19 min read · ~16 pages · Grade level 10.7 · Accepted 2024-01-26 16:25:21

Key Financial Figures

  • $37,500 — ments, which are not expected to exceed $37,500, in total. 4 Who can help answer my

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 29 Compensation Discussion and Analysis 29 Compensation Committee Report 40 Summary Compensation Table 41 2023 Grants of Plan-Based Awards 43 2023 Options Exercised and Stock Awards Vested 45 Outstanding Equity Awards at Fiscal 2023 Year-End 45 Potential Payments Upon Termination, Including Termination After a Change in Control Transaction 48 CEO Pay Ratio 50 Pay Versus Performance 51 DIRECTOR COMPENSATION 55 AUDIT COMMITTEE REPORT 57 STOCKHOLDER MATTERS 59 Appendix A A- 1 PROXY STATEMENT INFORMATION CONCERNING SOLICITATION AND VOTING We are soliciting proxies from our stockholders to vote at our 2024 Annual Meeting of Stockholders, or at any continuation, postponement or adjournment thereof, for the purposes discussed in this proxy statement. The annual meeting will be held virtually at 5:00, p.m. Eastern time on Wednesday, March 6, 2024, at www.proxydocs.com/ENTA. For more information on how to access the virtual meeting, please visit the &#x201c;Investors &#x2013; 2024 Annual Meeting Materials&#x201d; section of our website at www.enanta.com or contact Investor Relations at (617) 607-0710. The proxy materials, including this proxy statement and our 2023 annual report to stockholders, are being distributed and made available on the internet at the &#x201c;Investors &#x2013; 2024 Annual Meeting Materials&#x201d; section of our website at www.enanta.com on or about January 26, 2024. This proxy statement contains important information for you to consider when deciding how to vote on the matters brought before the meeting. Please read it carefully. All references in this proxy statement to a particular year, e.g., 2023, refer to our twelve-month fiscal year ended on September 30 of that year, e.g., September 30, 2023, unless the context indicates otherwise. QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING AND VOTING Why did I receive these materials? We are soliciting proxies

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.